X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab-containing therapy (24) 24
humans (19) 19
index medicus (19) 19
oncology (18) 18
female (16) 16
breast cancer (13) 13
chemotherapy (11) 11
neoadjuvant chemotherapy (11) 11
randomized phase-ii (11) 11
breast neoplasms - drug therapy (8) 8
metastasis (8) 8
review (8) 8
molecular targeted therapy (7) 7
open-label (7) 7
triple-negative breast cancer (7) 7
1st-line treatment (6) 6
angiogenesis (6) 6
angiogenesis inhibitors - therapeutic use (6) 6
bevacizumab (6) 6
cancer (6) 6
growth-factor receptor (6) 6
prognosis (6) 6
trial (6) 6
triple negative breast neoplasms - drug therapy (6) 6
triple negative breast neoplasms - metabolism (6) 6
triple negative breast neoplasms - pathology (6) 6
antineoplastic agents - therapeutic use (5) 5
breast neoplasms - metabolism (5) 5
neoadjuvant therapy (5) 5
neoplasm metastasis (5) 5
obstetrics & gynecology (5) 5
patients (5) 5
treatment outcome (5) 5
tumors (5) 5
animals (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
clinical trials (4) 4
combination (4) 4
double-blind (4) 4
endothelial growth-factor (4) 4
expression (4) 4
middle aged (4) 4
phase-ii trial (4) 4
phase-iii trial (4) 4
targeted therapies (4) 4
vascular endothelial growth factor (4) 4
aged (3) 3
androgen receptor (3) 3
angiogenesis inhibitors - adverse effects (3) 3
antiangiogenic therapy (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
breast neoplasms - pathology (3) 3
cancer therapies (3) 3
chemotherapy, adjuvant (3) 3
disease progression (3) 3
drug therapy (3) 3
estrogen-receptor (3) 3
kinases (3) 3
medical prognosis (3) 3
molecular characterization (3) 3
neovascularization, pathologic - drug therapy (3) 3
paclitaxel (3) 3
pharmacology & pharmacy (3) 3
poly polymerase (3) 3
receptor, erbb-2 - metabolism (3) 3
receptors, estrogen - metabolism (3) 3
receptors, progesterone - metabolism (3) 3
research (3) 3
signal transduction (3) 3
triple negative breast neoplasms - diagnosis (3) 3
triple negative breast neoplasms - genetics (3) 3
triple negative breast neoplasms - mortality (3) 3
triple negative breast neoplasms - therapy (3) 3
administration, metronomic (2) 2
aged, 80 and over (2) 2
analysis (2) 2
angiogenesis inhibitors - administration & dosage (2) 2
angiogenesis inhibitors - pharmacology (2) 2
anthracycline (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
article (2) 2
basal-like (2) 2
bevacizumab - therapeutic use (2) 2
biology (2) 2
biomarkers (2) 2
biomarkers, tumor (2) 2
breast (2) 2
breast neoplasms - diagnosis (2) 2
capecitabine (2) 2
carcinoma (2) 2
care and treatment (2) 2
cell biology (2) 2
chemistry, medicinal (2) 2
clinical trial (2) 2
clinical trials as topic (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Imaging, ISSN 0899-7071, 2016, Volume 41, pp. 1 - 6
Journal Article
JOURNAL OF BREAST CANCER, ISSN 1738-6756, 09/2019, Volume 22, Issue 3, pp. 341 - 361
Breast cancer (BC) is still the most common cancer among women worldwide. Amongst the subtypes of BC, triple negative breast cancer (TNBC) is characterized by... 
CONJUGATE GLEMBATUMUMAB VEDOTIN | FACTOR RECEPTOR | BEVACIZUMAB-CONTAINING THERAPY | CHEMOTHERAPY | TRIAL | INHIBITION | MESSENGER-RNA | ONCOLOGY | RANDOMIZED PHASE-II | Triple negative breast neoplasms | Clinical trial | TRANSFORMING-GROWTH-FACTOR | Drug therapy | EXPRESSION | 일반외과학
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 08/2015, Volume 9, pp. 4303 - 4318
Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative... 
Nab-paclitaxel | Docetaxel | Paclitaxel | Bevacizumab | paclitaxel | 1ST-LINE TREATMENT | CHEMISTRY, MEDICINAL | nab-paclitaxel | CALGB 40603 | BEVACIZUMAB-CONTAINING THERAPY | PATHOLOGICAL COMPLETE RESPONSE | PHASE-II TRIAL | PREOPERATIVE TREATMENT | NEOADJUVANT CHEMOTHERAPY | docetaxel | ALBUMIN-BOUND PACLITAXEL | bevacizumab | PHARMACOLOGY & PHARMACY | CLINICAL-PRACTICE | Humans | Middle Aged | Treatment Outcome | Triple Negative Breast Neoplasms - mortality | Triple Negative Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Albumins - therapeutic use | Taxoids - therapeutic use | Neoplasm Metastasis | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Triple Negative Breast Neoplasms - metabolism | Triple Negative Breast Neoplasms - pathology | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Antineoplastic Agents, Phytogenic - therapeutic use | Taxoids - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Antimitotic agents | Patient outcomes | Breast cancer | Forecasts and trends | Antineoplastic agents | Drug therapy | Medical statistics | Drugs | Disease | Estrogens | Clinical trials | Oncology | Metastasis | Information management | Cancer therapies | Metastases | Nanoparticles | Literature reviews | Receptors | Biological products | Vital signs | Gene expression | ErbB-2 protein | Patients | Quality of life | Progesterone receptors | Chemotherapy | Womens health | Medical prognosis | Progesterone | Taxanes | Tumors
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 07/2014, Volume 12, Issue 7, pp. 1028 - 1059
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance,... 
PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | UNRESECTABLE LIVER METASTASES | BEVACIZUMAB-CONTAINING ARMS | ONCOLOGY | HIGH-DOSE LEUCOVORIN | POSTPROGRESSION SURVIVAL-TIME | 1ST-LINE COMBINATION CHEMOTHERAPY | KRAS WILD-TYPE | CAPECITABINE PLUS OXALIPLATIN | METASTATIC COLORECTAL-CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Bevacizumab | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Deoxycytidine - adverse effects | Leucovorin - therapeutic use | Cetuximab | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Membrane Proteins - genetics | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects
Journal Article
Cancer Cell, ISSN 1535-6108, 12/2014, Volume 26, Issue 6, pp. 880 - 895
Journal Article
Japanese journal of clinical oncology, ISSN 0368-2811, 2014, Volume 44, Issue 3, pp. 197 - 207
The development of new blood vessels is a crucial step in breast cancer growth, progression and dissemination, making it a promising therapeutic target. Breast... 
Clinical trial | Breast cancer | Antiangiogenic therapy | Predictive biomarker | clinical trial | CONTRAST-ENHANCED MR | 1ST-LINE TREATMENT | antiangiogenic therapy | breast cancer | OPEN-LABEL | PACLITAXEL PLUS BEVACIZUMAB | BEVACIZUMAB-CONTAINING THERAPY | PHASE-III TRIAL | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | DOUBLE-BLIND | predictive biomarker | ANTI-VEGF THERAPY | ENDOTHELIAL GROWTH-FACTOR | Predictive Value of Tests | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Vascular Endothelial Growth Factor A - metabolism | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Breast Neoplasms - metabolism | Angiogenesis Inhibitors - administration & dosage | Receptors, Vascular Endothelial Growth Factor - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Angiogenesis Inhibitors - therapeutic use | Biomarkers, Tumor - metabolism | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Angiogenesis Inhibitors - pharmacology | Clinical Trials as Topic | Breast Neoplasms - blood supply | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Breast Neoplasms - diagnosis | Protein Kinase Inhibitors - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Review
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2014, Volume 13, Issue 12, pp. 3175 - 3184
Journal Article
Breast Care, ISSN 1661-3791, 07/2015, Volume 10, Issue 3, pp. 159 - 166
Triple-negative breast cancer (TNBC) is a heterogeneous disease comprised of several biologically distinct subtypes. However, treatment is currently mainly... 
Review Article | Subtypes | Targeted therapy | PARP inhibitors | Bevacizumab | Immune-checkpoint inhibitors | Triple-negative breast cancer | 1ST-LINE TREATMENT | OPEN-LABEL | PLUS PACLITAXEL | COMBINATION | BEVACIZUMAB-CONTAINING THERAPY | ESTROGEN-RECEPTOR | OBSTETRICS & GYNECOLOGY | TRIAL | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | RANDOMIZED PHASE-II | PROGESTERONE-RECEPTOR | Review
Journal Article
Antioxidants & Redox Signaling, ISSN 1523-0864, 08/2016, Volume 25, Issue 6, pp. 337 - 370
Journal Article